(Q24234749)

3

0 references

Nick Huband

5

0 references

Klaus Lieb

6

object named as

Klaus Lieb

0 references

author name string

Jutta Stoffers

1

0 references

Birgit A Völlm

Cochrane Database of Systematic Reviews

2

0 references

language of work or name

English

0 references

publication date

2010

0 references

published in

0 references

issue

6

0 references

page(s)

CD005653

0 references

cites work

DSM-IV personality disorders in the National Comorbidity Survey Replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Pharmacological interventions for people with borderline personality disorder

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

The diagnostic interview for borderline patients

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Meta-analyses involving cross-over trials: methodological issues

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

The interface between borderline personality disorder and bipolar spectrum disorders

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Oxcarbazepine in the treatment of borderline personality disorder: a pilot study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Risperidone in the treatment of schizotypal personality disorder.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Efficacy of phenelzine and haloperidol in borderline personality disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Long-term outcome in personality disorders

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

The prevention of recurrent suicidal acts

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Fluoxetine in the treatment of borderline and schizotypal personality disorders

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Fluoxetine in borderline personality disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Venlafaxine in the treatment of borderline personality disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Paradoxical effects of amitriptyline on borderline patients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

A trial of carbamazepine in borderline personality disorder.

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Topiramate reduced aggression in female patients with borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Quetiapine in the treatment of borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Functional Impairment in Patients With Schizotypal, Borderline, Avoidant, or Obsessive-Compulsive Personality Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Mental Health Service Utilization by Borderline Personality Disorder Patients and Axis II Comparison Subjects Followed Prospectively for 6 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Aripiprazole treatment of patients with borderline personality disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Olanzapine versus placebo in the treatment of borderline personality disorder

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Chronic depression and comorbid personality disorders: response to sertraline versus imipramine

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Treatment of borderline personality disorder with risperidone

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169794

Reliability and validity of the borderline personality disorder severity index

29 November 2018

1 reference

12 December 2020

Response of borderline patients to loxapine and chlorpromazine

1 reference

12 December 2020

Pharmacological prevention of suicidal behaviour

1 reference

12 December 2020

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

1 reference

12 December 2020

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

1 reference

12 December 2020

Amitriptyline and haloperidol in unstable and schizotypal borderline disorders

1 reference

12 December 2020

Behavioral dyscontrol in borderline patients treated with amitriptyline

1 reference

12 December 2020

Fluoxetine trial in borderline personality disorder

1 reference

12 December 2020

Haloperidol vs. phenelzine in continuation therapy of borderline disorder

1 reference

12 December 2020

Clozapine treatment of borderline patients: a preliminary study

1 reference

12 December 2020

Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes

1 reference

12 December 2020

Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum

1 reference

12 December 2020

Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy

1 reference

12 December 2020

Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial

1 reference

12 December 2020

Topiramate treatment of aggression in male borderline patients

1 reference

12 December 2020

The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes

1 reference

12 December 2020

Psychoanalytic Investigation of and Therapy in the Border Line Group of Neuroses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD005653.PUB2

1 reference

1 reference

1 reference

PubMed publication ID

20556762

1 reference